Hq Spclt Pharma Company Profile

✉ Email this page to a colleague

HQ SPCLT PHARMA has fourteen approved drugs.

There are six US patents protecting HQ SPCLT PHARMA drugs.

There are twelve patent family members on HQ SPCLT PHARMA drugs in nine countries and ninety-two supplementary protection certificates in fifteen countries.

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	INJECTABLE;INJECTION	214172-002	Dec 2, 2022	AP	RX	No	No		⤷ Subscribe				⤷ Subscribe
Hq Spclt Pharma	IMIPENEM AND CILASTATIN	cilastatin sodium; imipenem	POWDER;INTRAVENOUS	207594-001	Dec 12, 2019	AP	RX	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984	5,562,925	⤷ Subscribe
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016	6,528,540*PED	⤷ Subscribe
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992	6,096,331	⤷ Subscribe
Hq Spclt Pharma	CISPLATIN	cisplatin	INJECTABLE;INJECTION	018057-002	Approved Prior to Jan 1, 1982	5,562,925	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
European Patent Office	2948379	⤷ Subscribe
World Intellectual Property Organization (WIPO)	2017184188	⤷ Subscribe
Australia	2016403510	⤷ Subscribe
Australia	2014228155	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	CR 2014 00050	Denmark	⤷ Subscribe	PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
2603514	2019014	Norway	⤷ Subscribe	PRODUCT NAME: A COMBINATION OF VABORBACTAM, AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE; REG. NO/DATE: EU/1/18/1334/001 20181122
2957286	6/2019	Austria	⤷ Subscribe	PRODUCT NAME: PATIROMER UND SEINE CALCIUM-SALZE; REGISTRATION NO/DATE: EU/1/17/1179 (MITTEILUNG) 20170721
2603514	132019000000051	Italy	⤷ Subscribe	PRODUCT NAME: COMBINAZIONE DI VABORBACTAM E/O UN SUO SALE E/O UN SUO IDRATO, E MEROPENEM, E/O UN SUO SALE E/O UN SUO IDRATO, IN PARTICOLARE MEROPENEM TRIIDRATO(VABOMERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1334, 20181122
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.